DRW Securities’s Endocyte, Inc. Common Stock ECYT Stock Holding History

DRW Securities’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-20,000	Closed	-$476K	–	185
2014 Q1	$476K	Buy	+20,000	New	+$290K	0.04%	78

Other funds holding ECYT

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DRW Securities's ECYT Position: Q4 2017 in Review

DRW Securities sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2017, closing a stake of 11,000 shares — an estimated $16K sold.

DRW Securities first reported a position in ECYT in Q1 2016 and held it in 4 quarters. The position peaked at $93K in Q1 2016. 71 funds tracked by Wall St. Rank hold ECYT as of Q4 2017.

DRW Securities reported no remaining Endocyte, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
DRW Securities sold 11,000 Endocyte, Inc. Common Stock shares in Q4 2017, an estimated $16K.
DRW Securities first reported a position in Endocyte, Inc. Common Stock in Q1 2016 and held it in 4 quarters.
DRW Securities's Endocyte, Inc. Common Stock position peaked at $93K in Q1 2016.
71 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2017.

Based on DRW Securities's 13F filing for Q4 2017, filed 14 Feb 2018.